SAN ANTONIO, Texas — BBG Advanced Therapies, a subsidiary of nonprofit BioBridge Global, today announced a collaboration with Kite, a Gilead Company and global leader
SAN ANTONIO, Texas — BBG Advanced Therapies (BBG AT), a subsidiary of San Antonio based nonprofit BioBridge Global (BBG), has entered into a collaboration with
Cell and gene therapies (CGTs) are opening new possibilities for patients with cancer, rare diseases, blood disorders, and autoimmune conditions. As these groundbreaking therapies move
Technology in Biomanufacturing Cleanrooms Cleanroom technology continues to evolve as industries face stricter regulatory requirements, higher product quality expectations, and increasing pressure to reduce contamination
BBG Advanced Therapies Subsidiary of BioBridge Global is advancing our role as an integrated partner for advanced therapy development by delivering cGMP-compliant umbilical cord tissue
Blueprint for Breakthroughs is a LinkedIn newsletter published by Adrienne B. Mendoza, MHA, SVP BioBridge Global and Chief Operating Officer (COO), BBG Advanced Therapies Originally
In a recent webinar, Future Proofing Cell & Gene Therapy: Strategies to Secure Your Leukapheresis Supply Chain, Heather Munoz, Principal of Global Market Development, and James
South Texas Blood & Tissue COO recognized for exceptional leadership and contributions to donor services and transfusion medicine. Audra Taylor, Chief Operating Officer of South
Blueprint for Breakthroughs is a LinkedIn newsletter published by Adrienne B. Mendoza, MHA, SVP BioBridge Global and Chief Operating Officer (COO), BBG Advanced Therapies Originally
Honorees recognized by the San Antonio Business Journal reflect innovation, leadership and impact across BioBridge Global and its subsidiaries. Four members of the team at
Emerging discoveries in blood group science highlight the need for advanced testing, donor diversity, and adaptable strategies across transfusion medicine and biotherapeutics. A new blood
Rohini Thevi Guntnur, Ray Rendon III, Joseph Higdon, Deidre Cacchillo, and Rogelio Zamilpa Therapeutic efficacy, reliability, and availability of cell, gene, and tissue-derived therapies have